April 9, 2021 07:22 AM EDT
Coronavirus

Covid-19 roundup: Lil­ly/In­cyte's Olu­mi­ant plus remde­sivir com­bo whiffs PhI­II; France rec­om­mends mix­ing vac­cines among younger As­traZeneca re­cip­i­ents

Max Gelman

Senior Editor

Eli Lil­ly has won three emer­gency use au­tho­riza­tions for Covid-19 treat­ments, two for its an­ti­body cock­tail con­tain­ing bam­lanivimab and one fea­tur­ing its In­cyte-parn­tered drug Olu­mi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times